Abstract 4007: Efficacy of vepafestinib in preclinical models of RET fusion-driven sarcoma models
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4007
Abstract: Background: Vepafestinib (TAS0953/HM06, Vepa) is a 2nd generation RET-selective inhibitor that effectively penetrates the brain, and inhibits the wildtype RET kinase domain (KD) and RET KD mutants (G810, V804, Y806, L730) (presented at AACR-NCI-EROTC 2021… read more here.
Keywords: hmsc ret; efficacy; ret fusion; preclinical models ... See more keywords